BRUKER CORP BRKRP
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
4/9
Piotroski F — financial health
2.98
Altman Z″ — distress risk · safe
-265.1%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.4B | -$8.6M | $1.6B | $43.3M | $2.5B |
| 2024 | $3.4B | $113.1M | $1.6B | $136.0M | $1.8B |
| 2023 | $3.0B | $427.2M | $1.5B | $243.2M | $1.4B |
| 2022 | $2.5B | $296.6M | $1.3B | $145.2M | $1.1B |
| 2021 | $2.4B | $277.1M | $1.2B | $190.4M | $1.1B |
| 2020 | $2.0B | $157.8M | $939.8M | $235.0M | $974.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-06-15 | Option exercise | 2,000 | $22.19 |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-06-15 | Sell | 2,000 | $54.76 |
| Bernard Thierry | director | 2026-05-15 | Grant | 2,886 | — |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-05-15 | Option exercise | 2,000 | $22.19 |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-05-15 | Sell | 2,000 | $43.90 |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-04-15 | Option exercise | 2,000 | $22.19 |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-04-15 | Sell | 2,000 | $39.90 |
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2026-03-13 | Option exercise | 2,000 | $22.19 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.98 (safe)
- Working capital / assets 0.15
- Retained earnings / assets 0.378
- EBIT / assets 0.011
- Equity / liabilities 0.663
Source: SEC EDGAR filings · CIK 0001109354 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.